Spondyloarthritis & psoriatic arthritis
Improved Pain, Morning Stiffness, and Fatigue With Bimekizumab in Axial Spondyloarthritis: Results From the Phase III BE MOBILE Studies
Authors' conclusion
Bimekizumab treatment led to rapid improvements in levels of pain and morning stiffness. Substantial improvements were seen in all domains across the full disease spectrum of axSpA and continued to week 52.
Study context
- Population
- Patients with nr-axSpA and r-axSpA
- Comparison
- Bimekizumab 160 mg every 4 weeks vs placebo; all patients received bimekizumab from week 16
Methodological detailsphase III, placebo-controlled
- Phase III
- Placebo-controlled
Primary result
As reported in the abstract
Pain, morning stiffness and fatigue · week 16
- Lower mean nocturnal spinal pain, total spinal pain and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores with bimekizumab vs placebo (nominal except for nocturnal spinal pain)
- all P ≤ 0.001
- Higher FACIT-Fatigue scores with bimekizumab vs placebo
- nominal P < 0.05
Further findings
Pain, morning stiffness and fatigue · week 52
- Improvements continued to week 52 in continuous bimekizumab and placebo-bimekizumab switchers
- Over half of patients were FACIT-Fatigue responders (≥ 8-point increase)
Original publication
Improved Pain, Morning Stiffness, and Fatigue With Bimekizumab in Axial Spondyloarthritis: Results From the Phase III BE MOBILE Studies. J Rheumatol. Published 15 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →